Cosmo N.V. (CMHC.SW) is currently considered halal (Sharia-compliant), per In-house ratio engine (last assessed 2026-08-27). See the full ratio breakdown and business-activity screen below for the reasoning.
Computed from Yahoo Finance fundamentals (Tier-4 provider, no filing available), balance sheet as of 2025-12-31. CMHC.SW files no SEC reports, so these ratios come from the issuer's own published statements rather than XBRL.
Business activity: cleared (no excluded categories detected)
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 0.80% | 30.00% | Pass |
| Interest-bearing investments | 11.90% | 30.00% | Pass |
| Non-permissible income | 1.01% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 1.35% | 33.00% | Pass |
| Interest-bearing investments | 20.04% | 33.00% | Pass |
| Non-liquid assets | 76.02% | at least 20.00% | Pass |
| Non-permissible income | 1.01% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 1.35% | 33.33% | Pass |
| Cash + interest-bearing securities | 20.04% | 33.33% | Pass |
| Accounts receivable | 23.98% | 33.33% | Pass |
| Non-permissible income | 1.01% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 1.35% | 33.33% | Pass |
| Cash + interest-bearing securities | 20.04% | 33.33% | Pass |
| Accounts receivable | 23.98% | 50.00% | Pass |
| Non-permissible income | 1.01% | 5.00% | Pass |
Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 0.64% | 33.00% | Pass |
| Cash + interest-bearing securities | 9.47% | 33.00% | Pass |
| Accounts receivable | 1.86% | 33.00% | Pass |
| Non-permissible income | 1.01% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 0.68% | 33.00% | Pass |
| Cash + interest-bearing securities | 10.14% | 49.00% | Pass |
| Accounts receivable | 1.99% | 49.00% | Pass |
| Non-permissible income | 1.01% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 0.68% | 33.33% | Pass |
| Cash + interest-bearing securities | 10.14% | 33.33% | Pass |
| Accounts receivable | 12.14% | 49.00% | Pass |
| Non-permissible income | 1.01% | 5.00% | Pass |
Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 37.90 | NEUTRAL |
| Stochastic %K (14) | 22.22 | NEUTRAL |
| CCI (20) | -124.07 | BUY |
| Williams %R (14) | -77.78 | NEUTRAL |
| MACD (12,26,9) | 0.01 | BUY |
| ROC (10) | -3.35 | SELL |
| Momentum (10) | -1.90 | SELL |
| EMA (10) | 55.48 | SELL |
| SMA (10) | 55.44 | SELL |
| EMA (20) | 56.78 | SELL |
| SMA (20) | 56.71 | SELL |
| EMA (30) | 58.09 | SELL |
| SMA (30) | 57.98 | SELL |
| EMA (50) | 60.87 | SELL |
| SMA (50) | 60.72 | SELL |
| EMA (100) | 66.95 | SELL |
| SMA (100) | 68.29 | SELL |
| EMA (200) | 74.45 | SELL |
| SMA (200) | 82.51 | SELL |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Healthcare · Drug Manufacturers - General
Cosmo N.V., a life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cortiment, an oral tablet formulation that delivers budesonide directly to the lumen of the colon; Eleview, an injectable composition to allow endoscopists with excision of gastrointestinal lesions; Lumeblue, a diagnostic drug for the visualisation of colorectal lesions during colonoscopies; Aemcolo/Rifamycin, a pharmaceutical drug product in form of tablets that is approved for the treatment of travelers' diarrhoea; and Clascoterone, which is in phase-3 clinical trial for the treatment of male pattern hair loss. It is also developing novel UC treatment, which is in phase-2 clinical trial for the treatment of distal inflammatory bowel disease/distal ulcerative colitis/proctitis; BAD Treatment (CB-01-33), which is in phase-2 clinical trial for the treatment of colesevelam formulation/bile acid diarrhea; and CB-03-10, which is in phase-1 clinical trial for the treatment of oncology solid tumors, as well as provides Cosmo's AI technology, a GI Genius intelligent endoscopy system. The company was formerly known as Cosmo Pharmaceuticals N.V. and changed its name to Cosmo N.V. in April 2026. The company was founded in 1997 and is headquartered in Dublin, Ireland.
Background via Yahoo Finance — informational, not part of the verdict.
Peer movement computing — it will appear here on its own.
NO DATA 0 buys · 0 sells
NEUTRAL report date 2026-09-01 · Asset managers net 934180 (-19048)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.
